Status:
COMPLETED
Telederm and Bullous Pemphigoid
Lead Sponsor:
Emory University
Collaborating Sponsors:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions:
Bullous Pemphigoid
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to improve the quality of future clinical trials in bullous pemphigoid (BP), the investigators will monitor repeated measurement data from patients with BP on standard-of-c...
Detailed Description
The study team plans to recruit 45 subjects from the autoimmune blistering disease clinic at Emory Dermatology Clinic. The plan is to improve the quality of future clinical trials in bullous pemphigoi...
Eligibility Criteria
Inclusion
- Males or females \> age 18
- Clinical and histological confirmation of bullous pemphigoid including at least subepidermal separation on H\&E or a positive direct immunofluorescence along with indirect immunofluorescence which demonstrates staining to the roof on salt split skin or ELISA positivity for BP180 and/or BP230 autoantibodies
- Baseline BPDAI-TAS \>5
Exclusion
- Subjects who are unable to consent, language barriers, or other unspecified reason that in the opinion of the investigator makes the subject unsuitable for enrollment. Subjects that do not meet all of the enrollment criteria may not be enrolled. Any violations of these criteria must be reported in accordance with IRB Policies and Procedures.
Key Trial Info
Start Date :
March 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 6 2023
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04728854
Start Date
March 15 2021
End Date
October 6 2023
Last Update
October 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory Dermatology Clinic
Atlanta, Georgia, United States, 30322